Tianjing biology and MorphoSys reached strategic cooperation on the development of tumor innovative biological drug mor210

November 16, 2018 / Meitong news agency / -- Tianjing Biotechnology (Shanghai) Co., Ltd (hereinafter referred to as "Tianjing biology"), a research and development company focusing on tumor immunity and autoimmune disease treatment, and morphasys, a German company, today jointly announced a strategic cooperation on the development of tumor immunity innovative biological medicine mor210 Mor210 is an antibody against C5aR, which is in the preclinical development stage and has good development potential in tumor immunology According to the agreement, Tianjing biology will have the exclusive rights and interests of mor2 in the Greater China and South Korea This signing is another in-depth cooperation between the two sides after mor202 Tianjing biology and morphasys have reached a strategic cooperation on the development of tumor innovative biological drug mor210 Based on the terms of mor210 cooperation, Tianjing biology will have exclusive development and commercial rights and interests including Mainland China, Hong Kong, Taiwan and South Korea The total amount of equity transfer reached US $105 million, including development and commercialization milestone costs At the same time, Tianjing biology will also be responsible for the first phase of clinical trial and proof of concept test POC (proof of concept) in the field of mor210 tumor diseases, including the first human body (FIH) in the world As part of the cooperative rights and interests, Tianjing biology will be able to obtain the gradient share of mor210 overseas net sales and royalties The blocking of immune checkpoint released from tumor has become one of the important strategies to fight against cancer Mor210 is an important discovery of morphasys in tumor immunology It blocks C5aR directly and changes the microenvironment of tumor "In view of the good cooperation between MorphoSys and Tianjing biology on the mor202 project We believe that Tianjing biology has strong strength to promote the clinical development of mor210 in Greater China and lead the POC clinical trial of the product in the field of global oncology This contract will push the cooperation between the two sides to a new height, and we believe that we can usher in a win-win situation " Dr Simon Moroney, chief executive of morphasys, said "We are very excited about the potential of mor210 as a tumor immunotherapy program and look forward to further cooperation with morphasys." Dr Zang Jingwu, CEO of Tianjing biology, said: "this project further strengthens the innovative biological drug pipeline of Tianjing biology aiming at" global first research "and" best in class " We hope that these innovative products can better meet the clinical needs of China and the world in this field " About mor210 and C5aR mor210 are based on the hucalplatinum ® technology development of morphasys, which are currently in the preclinical stage, and are human antibodies against C5aR C5aR is a complement 5A receptor, which is regarded as an innovative target in the field of tumor immunity and autoimmune diseases Aiming at the large amount of C5aR produced by tumor, it can help immunosuppression and promote the formation of tumor microenvironment by attracting and activating MDSCs The purpose of mor210 is to block the interaction between C5a and its receptor, so as to neutralize the immunosuppressive function of MDSCs and make immune cells attack tumors About Tianjing Bio: Tianjing bio is a global innovative bio drug R & D enterprise based in China The company focuses on innovative bio drug R & D in the field of tumor immunity and autoimmune diseases Tianjing biology was established in 2017 by the merger of Sanjing biology and tianshizhen, and quickly formed an experienced and international level R & D team In the same year, Tianjing biology completed round B financing of US $150 million On June 29, 2018, it successfully completed the C round financing of US $220 million again, and became one of the largest C round financing in the field of innovative drugs in China It was led by Hony capital and invested by a number of well-known institutions Tianjing bio is committed to providing global patients with innovative bio medicine with global initiative and similar optimal potential At present, Tianjing biology has launched a phase II clinical research and development project, and plans to conduct other multi center clinical trials including phase II and phase III in China and the United States About morphasys: morphasys is a biopharmaceutical company dedicated to developing innovative and differentiated chemotherapy solutions for critical patients Based on the company's leading position in the field of antibody research and development, MorphoSys and its partners have jointly developed and promoted more than 100 candidate products, 29 of which have entered clinical development The extensive product pipeline of morphasys mainly consists of two parts: the product portfolio independently developed and developed by morphasys, and the product portfolio developed in cooperation with external partners In 2017, the proprietary antibody technology product of MorphoSys, tremfya ® (guselkumab), obtained the marketing license for the treatment of moderate to severe plaque psoriasis in the United States, the European Union and Canada, and was marketed by Janssen, the prescription drug Department of Johnson & Johnson.